U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07579429) titled 'Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)' on May 05.
Brief Summary: This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and pterostilbene at different doses. The primary goals of the study are:
* to assess if study drug improves cytopenias in patients
* to determine safety of the study drug in patients
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Clonal Cytopenia of Undetermined Significance
Myelodysplastic Syndrom...